GEN Exclusives

More »

GEN News Highlights

More »
Nov 24, 2008

XDx to Restructure

  • XDx is reprioritizing its business efforts. The firm will increase its research, development, and commercial activities in support of AlloMap®. In addition, it will restructure its internal development program, pursue external research collaborations in lupus, as well as suspend development activities in lung transplant. A staff reduction of 25 positions and other cost-saving measures will be undertaken as well.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »